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Abstract
The common cold is a viral infection with important economic burdens in Western countries. The research and
development of nutritional solutions to reduce the incidence and severity of colds today is a major focus of interest, and
larch arabinogalactan seems to be a promising supportive agent. Arabinogalactan has been consumed by humans for
thousands of years and is found in a variety of common vegetables as well as in medicinal herbs. The major commercial
sources of this long, densely branched, high-molecular-weight polysaccharide are North American larch trees. The aim
of this article is to review the immunomodulatory effects of larch arabinogalactan derived from Larix laricina and Larix
occidentalis (North American Larix species) and more specifically its role in the resistance to common cold infections. In
cell and animal models, larch arabinogalactan is capable of enhancing natural killer cells and macrophages as well as the
secretion of pro-inflammatory cytokines. In humans a clinical study demonstrated that larch arabinogalactan increased
the body’s potential to defend against common cold infection. Larch arabinogalactan decreased the incidence of cold
episodes by 23 %. Improvements of serum antigen-specific IgG and IgE response to Streptococcus pneumoniae and
tetanus vaccination suggesting a B cell dependent mechanism have been reported in vaccination studies with larch
arabinogalactan, while the absence of response following influenza vaccination suggests the involvement of a T cell
dependent mechanism. These observations suggest a role for larch arabinogalactan in the improvement of cold
infections, although the mode of action remains to be further explored. Different hypotheses can be envisaged
as larch arabinogalactan can possibly act indirectly through microbiota-dependent mechanisms and/or have a
direct effect on the immune system via the gut-associated lymphoid tissue (GALT).
Keywords: Larch arabinogalactan, Common cold infections, Immune system, Vaccine, SCFA, Polysaccharides,
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Background
The common cold is an extremely common infection of
the upper respiratory tract. This viral illness represents
an enormous economic burden on Western society due
to loss of productivity and high medical costs [1]. On
average in the US, children have 6-8 and adults have 2-4
cold episodes per year [1]. Some authors estimated the
economic cost of lost productivity due to the common
cold as $25 billion each year ($16.6 billion due to on-
the-job productivity loss, $8 billion due to absenteeism,
and $230 million due to caregiver absenteeism) in the
US [2]. On average each US American spends $8.30 per
common cold episode on over-the-counter drugs. It is
accepted that viruses, not bacteria, cause common cold
infections [3] and more than 200 different types of
viruses have been identified, with the rhinoviruses being
the most common [4]. However, colds occasionally pre-
dispose individuals to bacterial complications. Nutrition
is known to affect the immune system and can modulate
resistance to infection [5]. The development of new
nutritional solutions that can enhance the immune
system’s response to environmental pathogens has been
of major interest in recent years. Amongst these
solutions, larch arabinogalactan presents the advantage
of enhancing the immune function [6], and thus is
speculated to protect against common colds. So far, only
a few reviews have been published on arabinogalactan
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[6, 7], while recent studies give more insights into their
effect on the immune system along with proposed
mechanisms of action. The purpose of this review is
to provide a comprehensive overview of the immu-
nomodulating properties of larch arabinogalactan
derived from North American Larix species (Eastern




Arabinogalactans (synonyms: Galactoarabinan, Ara-
bogalactan, Galactoarabinin) belong to a major group
of carbohydrates known as hemicelluloses, which are
non-starch polysaccharides that occur abundantly in
the primary and secondary cell walls of plant cells
and are widely spread throughout the plant kingdom.
In most plants, arabinogalactans occur in covalent
association with protein, either as proteoglycans or as
glycoproteins [7]. The protein moiety of arabinogalactan
associated proteins is typically rich in hydroxyproline,
serine, alanine, threonine, and glycine and is resistant to
proteolysis in its native state, a property that is
presumably conferred by extensive glycosylation [8, 9].
Arabinogalactan extracted from Larix spp. heartwood is
an exception, as it is not bound to protein, which is
evidenced by the complete absence of nitrogen during
elementary analysis of Larix laricina [10, 11].
Arabinogalactans have been part of the human diet for
thousands of years. They have been detected in seeds,
leaves, roots, fruit and xylem sap of representatives of all
higher plant families. Dietary sources of arabinogalactans
include leek seed, carrot, radish, pear, maize, wheat and
tomato [7]. Sources also include medicinal herbs such as
Echinacea species, Baptisia tinctoria, Curcuma longa,
and Angelica acutiloba [12] which are cultivated all over
the world.
In trees, arabinogalactans are widely present as minor,
water-soluble components of softwoods such as hemlock,
black spruce, parana pine, mugo pine, Douglas fir, incense
cedar, and juniper [13].
The major commercial sources of arabinogalactan are
the North American larch trees, which are genetically
different from Eurasian larch tree species [14]. The genus
Larix (Larches) is common throughout the world. Table 1
provides an overview of the different Larix species that
grow in specific regions [Table 1].
Both the concentration and distribution of arabinoga-
lactan varies between Larix species as well as within a
single species, but may constitute up to 35 % by weight
of dry heart wood of a larch tree [13, 15, 16]. Unique
properties of larch arabinogalactan include its complete
solubility and stability over a wide range of concentra-
tions, pHs and temperatures [17].
Arabinogalactan is composed of two monomers, D-
galactose and L-arabinose (in a 6:1 and 7.5:1 ratio in
Western larch and Siberian larch respectively), with
traces of uronic acid [7, 18]. Western larch arabinogalac-
tan consists of a (1→ 3)-β-D-galactopyranan main chain
with side (1→ 6)-linked groups of varying length to
every galactosyl unit; organised as a triple helical struc-
ture with varying morphologies. These features explain
why arabinogalactan forms a hydrocolloid in solution
[19, 20]. The Joint FAO/WHO Expert Committee on
Food Additives (JECFA) included arabinogalactan into
section “Jellifying Agents, Thickening Agents, Stabilizers
of Botanical Origin” and registered it under number E-
409. Larch arabinogalactan was approved by the Food
and Drug Administration in 1965 for direct addition to
food and gained Generally Recognized As Safe (GRAS)
notification in 2000. There is a Food Chemical Codex
Monograph for arabinogalactan available and the larch
arabinogalactan referred to here (ResistAid® brand) is
produced in line with this monograph and the accept-
ance criteria listed therein. It is classified as a dietary
fiber because it resists digestion by enzymes contained
both in saliva and the small intestine, hence entering the
large bowel intact, where it is fermented by the resident
microflora. Larch arabinogalactan has a strong safety
profile, according to a variety of toxicity studies carried
out since the 1960s [10, 21].
North American larch arabinogalactan displays molecu-
lar masses ranging between 16,000 and 100,000 Daltons
and presents a high molecular weight fraction (20 %), while
Eurasian larch species (such as Larix dahurica, Mongolian
larch) show neither of these characteristics [20]. In addition
to composition variation existing across different species,
the monosaccharide composition and molecular mass of
arabinogalactan macromolecules observed can also differ
within a single species depending on the specific isolation
and extraction procedures employed [22]. This variability
may account for the wide range of biological proper-
ties and activities documented, such as the protection
of gastrointestinal mucosa and large bowel function
[23], the support of digestive health by improving in-
testinal flora [6, 24, 25], the improvement of stress-
Table 1 Overview of different species of the genus Larix
growing throughout the world
Central Europe European larch Larix decidua
Japan Japanese larch Larix leptolepis/
Larix kaempferi
North America Eastern larch, tamarack tree Larix laricina
North America Western larch Larix occidentalis
Siberia Dahurian larch/Mongolian larch Larix dahurica/
Larix gmelinii
Siberia Siberian larch Larix sibirica
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induced gastrointestinal dysfunction [26], the effect on
vascular permeability [7], the effect in metastatic disease
[7] and the enhancement of immune function [7].
Larch arabinogalactan and common cold infections:
human trials
Larch arabinogalactan’s effects on the immune system
have been investigated through multiple human studies
with different objectives [Table 2].
Three clinical trials performed in free-living healthy
adults were retrieved from the literature. Two of these
studies explored the effect of larch arabinogalactan on
TNF-α in serum following four weeks’ supplementation
at 1.5 g/d. Results from both studies displayed different
results as one reported an increase on this parameter
while the other did not. Furthermore, other immune pa-
rameters explored (NK cells, immunoglobulins, immune
cells counts) were not affected by the supplementation
in either trial [12, 27]. The third study performed with a
higher dose of larch arabinogalactan (4 g/d) in 51 young
healthy adults did not evaluate the previous parameters
but rather demonstrated that 4 g/d of larch arabinoga-
lactan provided for 6 weeks in orange juice significantly
increased the percentage of blood CD8+ T-suppressor
cells compared to a placebo (p = 0.005) and increased
the proportion of monocytes in the lymphocyte fraction
(p = 0.05), independent of time. Lymphocyte prolifera-
tion was significantly increased at 6 weeks compared to
baseline in the arabinogalactan group, which was not the
case in the control group. Other parameters including
serum IgG levels, respiratory burst activity of neutro-
phils, NK cell number and B cell number remained
unchanged [28]. These three studies performed in
healthy adults suggest that larch arabinogalactan might
influence TNF-α secretion and modulate the proportion
of immune cells proportions while other parameters
such as immunoglobulin levels, NK cells levels and
activity or neutrophils activity seemed unaffected by the
supplementation, though the pattern of effects exerted
was different between studies. In these clinical trials
however, the relevance of the model (healthy subjects
and absence of immune challenge) and markers could be
questioned, as improvement of immune response can be
observed mainly in immune-challenged conditions. As
discussed in an expert’s review, the markers providing the
most useful indication to assess the immune-modulating
properties of nutraceuticals are those that involve either a
standard assessment of relevant symptoms (symptoms of
allergies or common infections) or those involving in vivo
responses to a defined challenge with allergens or antigens
(allergen provocation, vaccine response) [29].
Larch arabinogalactan has been tested in several of these
immune-challenge models. Riede et al. evaluated the effect
of larch arabinoglalactan on common cold infections in
healthy adults. This placebo-controlled, double-blind and
randomised trial was performed during the cold season of
2010/2011 with 199 healthy volunteers who had reported
at least 3 upper respiratory tract infections in the last
6 months. After daily administration of either 4.5 g of an
arabinogalactan preparation or placebo over a period of
12 weeks, it appeared that larch arabinogalactan (ResistAid®
brand) increased the body’s potential to defend against
infections [30]. The incidence of common cold infections
in the group supplemented with arabinogalactan was
significantly decreased compared to the placebo group in
both analysis sets: full analysis set (FAS, p = 0.038) and Per
Protocol (PP, p = 0.033). The number of cold episodes
strongly tended to decrease in the arabinogalactan group in
the FAS (p = 0.055), while in the PP analysis this decrease
of 23 % was statistically significant (p = 0.04) [Table 3] [30].
A trend for a reduction in the duration of cold episodes
was observed in supplemented subjects (p = 0.061). Inter-
estingly, self-reported severity of cold symptoms was higher
on the first day of cold episodes in subjects supplemented
with arabinogalactan while this difference was not observed
on the fifth day of cold episodes [30]. It has been suggested
that the highly variable subjective perception of a dis-
ease could be responsible for the difference noticed.
However, these results could also be explained by a
quicker and stronger immune response favoured by the
supplementation with arabinogalactan. Therefore, the
common symptoms of a cold such as redness, heat,
swelling, and pain, experienced more intensely by par-
ticipants on the first day of the trial could be attributed
to such an immune response.
More specific information on the enhancement of an im-
mune response following a challenge has been obtained
using the vaccine challenge method. The impact of a 10-
week supplementation period with 4.5 g/d of a proprietary
arabinogalactan preparation from larch tree (ResistAid®
brand) was studied in a vaccine model [31]. The
researchers demonstrated that the preparation selectively
enhanced the antibody response to vaccination against
Streptococcus pneumoniae and observed an increase in
pneumococcal IgG antibodies of various pneumococcal
antigens [31].
A similar study performed by the same research group
compared the effectiveness of the ResistAid® ingredient
at a daily dose of 1.5 g to a placebo, and demonstrated a
significant increase in IgG antibody response to tetanus
vaccine, while no improvement was observed following
influenza vaccine [32].
These results taken together suggest that larch arabino-
galactan can improve immunity by decreasing infections
and improving immunoglobulin response following a
standardized immune challenge. Doses used in these trials
suggest that larch arabinogalactan may improve immune
response at a dose as low as 1.5 g/d taken for several
Dion et al. Nutrition & Metabolism  (2016) 13:28 Page 3 of 11
Table 2 Summary of clinical studies on the effect of larch arabinogalactan on the immune system
Article Extract Challenge (Vaccine) Subjects Day for the
measures






1.5 or 4.5 g/day
For 60 days
Tetanus & influenza vaccines





➢ Tetanus IgG Group 1.5 g/day, day 60: significant rise in IgG
levels compared to placebo (p = 0.008)
Group 4.5 g/day group, day 45 & 60: significant
rise in IgG levels compared to baseline (p< 0.01)
but not compared to placebo










Common cold episode Reduce the incidence of common cold
infection (p = 0.055)
Reduce the number of subject affected
(p = 0.038)
Increase of the severity of symptoms
(p = 0.028)















➢ Pneumococcal IgG (subtypes 4,
6B, 9 V, 14, 18C, 19 F & 23 F)
Significant rise in IgG levels compared to
placebo in 2 antibodies subtypes (18C & 23 F)
at day 51 (p = 0.006 and p = 0.002) and day 72
(p = 0.008 and p = 0.041)
➢ Pneumococcal salivary IgA No effect
Day 0, 30,
31, 51 & 72
➢ WBCa count No significant difference compared to placebo
At day 72, rise in WBC compared to baseline
(p = 0.045)
No differences (clinically significant) in
lymphocytes, neutrophils, monocytes or
basophiles count
Significant rise of eosinophil count at day
30 (p = 0.006) and day 51 (p = 0.014)
➢ Inflammatory cytokinesa: ENA-78,
eotaxin, GM-CSF, IFNγ, IL10, IL12P40,
IL1RA, IL2, IL4, IL5, IL6, IL8, MCP-1,
MCP-3, PDGF-BB & TNF-α
Significant rise in IL6 between day 30 and 31
compared to placebo (p = 0.046)










➢ Haematology: WBCa, RBCa, haemoglobin,
hematocrit, neutrophils, lymphocytes,
monocytes, platelets
➢ Count of CD19 B lymphocytes, CD4 T
helper lymphocyte, CD8 T cytotoxic
lymphocytes & NK1.1 natural killer cells
➢ PBMCa (lymphocytes) proliferation
after exposure to PMA
➢ PMNa for oxidative burst activity
➢ Natural killer cells activity
➢ IgaG
Significant increase of % CD8+ cells at 6 weeks
after arabinogalactan compared to
control group (p = 0.005)
Significant increase in lymphocyte proliferation
at 6 weeks compared to baseline in the
arabinogalactan group (p < 0.05) only
Significant effect of group detected on
proportion of monocytes in the lymphocytes
fraction (p = 0.0497), though no significant
groupatime effect detected (p = 0.602).
No significant change in IgG levels, respiratory
burst activity of neutrophils, NK cell number














Table 2 Summary of clinical studies on the effect of larch arabinogalactan on the immune system (Continued)
Kim et al.
2002 [27]





Day 0 & 28 ➢ Vital signs: blood pressure, radial pulse,
respiration rate, temperature
No effect
➢ Complete blood count: WBC, neutrophils,
lymphocytes & monocytes
No effect
➢ NK cells quantitative No effect
➢ Complement properdin No effect
➢ TNF-α Significant decrease (p = 0.044)
➢ EBV VCA IgG Ab
➢ CMV IgG Ab
No effect
No effect
➢ Lactobacillus acidophilus stool culture
➢ Stool fungus culture for yeast
No effect
No effect
➢ Health related quality of life (SF-36) Increase of the bowel movement (75 %




(90 %) – different
concentration grades













➢ Stool culture No effect
➢ Health related quality
of life (SF-36)
No effect
aENA epithelial neutrophil activating peptide-78, GM-CSF granulocyte monocytes colony stimulating factor, IFNγ interferon gamma, IL interleukin, MCP monocyte chemotactic protein-1, MCP-3, PDGF platelet-derived
growth factor-BB or TNF tumour necrosis factor-alpha, PBMC peripheral blood mononuclear cells, PMN polymorphonuclear neutrophils, PMA phorbol 12-myristate 13-acetate, WBC White blood cells, RBC red blood cells,














weeks; however, more consistent results have been
obtained at a dose level of 4.5 g/d over several weeks. This
was seen both on vaccine models and on infection-
prevention models. Further clinical studies would be
required in order to confirm and clarify these findings,
such as the lack of response following influenza vaccine.
Effect of larch arabinogalactan on immune parameters:
preclinical studies
The immunostimulatory activity of larch arabinogalactan
has been investigated in various in vitro and in vivo studies.
These works have demonstrated activation of different
components of the immune system. An effect on natural
killer cells (NK cells), components of the nonspecific imme-
diate immune response to antigens, has been observed.
Hauer and Anderer’s ex vivo study, using human peripheral
blood mononuclear cells (PBMC), demonstrated larch
arabinogalactan’s ability to enhance NK cells’activity/cyto-
toxicity (i.e. ability to mediate spontaneous cytotoxicity
against tumour cells and virus-infected cells without prior
sensitisation by antigen) through a possible increase in
interferon-gamma (IFN-γ) [33]. The investigators also
highlighted larch arabinogalactan’s ability to induce the pro-
duction and/or release of pro-inflammatory cytokines such
as tumour necrosis factors-alpha (TNF-α), Interleukin-1
beta (IL-1β) and Interleukin-6 (IL-6) [33]. It has been
shown that tumoricidal and phagocytic activities of macro-
phages are enhanced by treatment with larch arabinogalac-
tan, and these activated cells exhibit increased production
of nitric oxide (NO), H2O2, TNF-α and IL-6 [34]. Further-
more, some but not all arabinogalactan-containing polysac-
charides from other sources have been shown to have
complement-fixing activity contributing to their immune-
modulating effects [35].
Studies done in vivo report that the number of mouse
spleen NK cells more than double compared to control
after 14 days exposure to intra-peritoneally injected
larch arabinogalactan [36]. The role played by larch ara-
binogalactan on the innate immune system is further
substantiated by Grieshop et al.’s in vivo study on dogs,
demonstrating that oral administration of larch arabino-
galactan (at doses of 0.55 g/day or 1.65 g/day for 10 days)
increases the number of circulating white blood cell
counts, namely neutrophils and eosinophils [17]. The
effect of larch arabinogalactan on the adaptive immune
system has also been studied. Grieshop et al.’s study on
dogs showed that the number of lymphocytes (CD4+T
helper, CD8+ cytotoxic T cells or B CD19+) was not
affected by larch arabinogalactan administration. Serum
IgG, IgM and IgA were also unaffected [17]. However,
Choi’s group affirms that the treatment of mice splenic
lymphocytes with arabinogalactan increased their
cytotoxic activity against tumour cells [34].
Pharmacokinetics of larch arabinogalactan
A number of studies aimed to investigate whether and how
arabinogalactan reaches the systemic circulation in order
to exert its effects on immunity. Larch arabinogalactan is
resistant to digestion by enzymes in the upper gastrointes-
tinal tract. It reaches the colon where it is slowly fermented
by the gastrointestinal microflora and thus, promotes the
growth of indigenous intestinal microflora such as Bifido-
bacterium and Lactobacillus acidophilus [12, 17, 25, 37]
similarly to other oligosaccharides [38]. The fermentation
of acacia gum arabinogalactan occurs both in proximal and
distal parts of the colon while other oligosaccharides such
as fructooligosaccharides may be fermented mostly in the
proximal part of the colon as shown with an in vitro model
of the human intestinal microbial ecosystem [39].
Carbohydrates of plant fibers are known to be digested
to varying degrees by the large bowel flora [40] and
Isphagula husk (an arabinoxylan of similar structure to
arabinogalactan) metabolization by the gut flora reaches
85-100 % in humans [24, 41]. Moreover, Vince et al. have
used an in vitro faecal incubation system and suggest
complete fermentation of acacia gum arabinogalactan
after 48 h [24]. The fermentation by the resident colonic
microflora of larch arabinogalactan results in the
production of the short chain fatty acids (SCFA) [Fig. 1],
butyrate, acetate and propionate [12, 17, 24], with the
Table 3 Summary of Riede et al.’s results on the effect of larch arabinogalactan on common cold
Population analysed FASa PPa set
Groups Placebo AGa Placebo AGa
Number of common cold episodes 1.06 ± 0.85 0.83 ± 0.82 1.10 ± 0.85 0.85 ± 0.82 *
Number of subjects affected by a cold episode 72.4 % 58.4 % * 74.4 % 59.8 % *
Duration of common cold episodes 8.3 ± 2.9 8.5 ± 2.8 - -
Intensity of symptoms after 5 days, documented in CRFa 8.5 ± 6.6 8.4 ± 6.8 - -
Intensity of symptoms after 5 days, from subject diary 5.85 ± 8.35 4.73 ± 8.08 - -
Intensity of symptoms at start, documented in CRFa 11.6 ± 6.3 13.3 ± 6.6 - -
Intensity of symptoms at start, from subject diary 11.5 ± 6.5 13.7 ± 6.9 * - -
aAG Arabinogalactan, CRF Case Report Form, FAS Full analysis set, PP Per protocol
Mean values (± SD) significantly different from the placebo: * p < 0.05
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latter two being predominantly produced [42]. Apart
from this pathway, the existence of a transfer of the
whole molecule of arabinogalactan to the systemic
immune system via the M-cells of the GALT [34] is
supported by the study of Yamashita et al. [43] on
antitumor peptidomannan KS-2, providing evidence that
orally administrated polysaccharides could be absorbed
via portal vein and intestinal lymphatics into the general
circulation with an intact molecular size.
According to these elements of evidence, arabinogalac-
tan may potentially exert its effects indirectly, relying on
SCFAs actions, or directly as a circulating agent.
Potential modes of action involved
Studies of the specific modes of action of larch arabino-
galactan support in part the two pathways developed
above. Indeed, arabinogalactan (similarly to other gut-
fermented polysaccharides) can possibly act indirectly
through microbiota-dependent mechanisms (i.e. rebalan-
cing microbiota composition in the gut, production of
SCFAs) and/or have a direct effect on the immune sys-
tem after passage from the gut lumen through the GALT
[Fig. 2].
The gut fermentation pathway generates SCFAs at high
concentrations through the breakdown of carbohydrates
[44]. These compounds, rapidly absorbed from the colonic
lumen, enter the portal and peripheral circulation [45],
regulate the metabolism, proliferation and differentiation
of colonic epithelial cells [46] as well as intestinal immun-
ity [38]. Their interactions with G-protein-coupled recep-
tors 41 and 43 (GPR41 and 43), expressed on a range of
immune cells [47, 48] may affect inflammatory responses
[48]. SCFAs regulate the leukocyte production of cyto-
kines, such as TNF-α, IFN-γ, IL-2, IL-6 and IL-10, as well
as eicosanoids and chemokines (e.g., MCP-1 and CINC-2)
[49, 50] and butyrate also affects leukocyte chemotaxis,
limiting the migration and, thus, the microbial pathogens’
destruction [49]. However, their exact and individual role
in these effects remains unclear. This particularly applies
to propionate and acetate, which are the two SCFAs
predominantly generated by arabinogalactan fermentation
[45]. In addition, Choi et al. suggested that mono- and
disaccharides generated from complex carbohydrates
during digestion could also exert an immunostimulating
role, despite little evidence supporting the influence of
simple carbohydrates on immune parameters [34].
There is also a possibility that larch arabinogalactan
expresses its clinical effects as intact macromolecules
rather than as fragments resulting from digestion [34],
though the mode of action involved is still unclear.
Fig. 1 Proposed mechanisms of action of larch arabinogalactan on immune system
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According to this second possible mode of action,
complex carbohydrates could exert an effect on gut-
associated immunity in the small intestine. This part of
the gut contains the GALT, consisting of immunoreac-
tive cells and organized lymphoid tissues, found in close
contact with the mucosal lining of the gut, and thus the
lumen. M-cells are specialised epithelial cells found in
the follicle-associated epithelium (FAE) and continuously
sample the lumen of the small intestine [51]. Soluble
proteins, particles and live microorganisms traverse the
M-cells by transcytosis and are delivered into a “pocket”
on the basolateral side of the cell that is packed with T
and B lymphocytes, macrophages and dendritic cells [51,
52]. Antigens seem to be unaltered by this translocation
[52] and once across the M-cell, it is processed by
antigen-presenting cells (APC) and presented to T lym-
phocytes that proliferate in place and stimulate local B
lymphocytes [52]. These then migrate to distant sites
[52], thus playing an important immunomodulatory role.
Despite these proposed mechanisms of action, several
findings from clinical studies remain to be explained. As
evidenced by Udani’s research group, arabinogalactan
supplementation failed to enhance immune response
following influenza vaccine, suggesting that this polysac-
charide confers a benefit in preparing the immune
system to manage infection with bacterial antigens, but
perhaps not with viral antigens [32]. Udani hypothesizes
that arabinogalactan is capable of stimulating the Peyer’s
patches in the gut as it traverses the intestines. The larch
polysaccharides may have a similar structure to these
Fig. 2 Larch arabinogalactan metabolism: simplified diagram of polysaccharide breakdown and the main routes of carbohydrate fermentation in
the large intestine
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potentially pathogenic bacteria, and therefore, provide a
low level of stimulation, which keeps an array of anti-
bodies ready in case the actual antigen appears [32]. This
hypothesis is consistent for the Streptococcus pneumo-
niae vaccine, as the vaccine is made of bacterial sugars
from 23 pneumococcal types. Vaccines produced from
bacterial polysaccharides are generally known to trigger
T-independent responses, i.e., directly inducing a B cell
response in the absence of T cell help. Other features of
this response include absence of immune memory and
induction of low-affinity antibodies [53]. However, the
effect of larch arabinogalactan on tetanus vaccine
response seems to be due to other mechanisms that
need to be identified. The tetanus vaccine is composed
of toxoids, a modified and harmless form of the tetanus
toxin protein (also named tetanospasmin and produced
by Clostridium tetani). The protection is often mediated
by B lymphocytes and IgG, as observed for Streptococcus
pneumoniae and tetanus vaccination [53]. However, T
cells could also be an important or the main effector of
the immune response, as it is the case for tuberculosis
vaccine (CD4+ T cells) or live attenuated influenza
intranasal vaccine (CD8+ T cells) [53]. Thus, it is
possible that arabinogalactan acts differently on these
various immune cell types, influencing the efficiency of
the vaccination through many different mechanisms.
The latter assertion is consistent with the effects exerted
by other plant polysaccharides that present the capacity
to positively modulate the influenza vaccine response. A
series of studies performed by Vos et al. shows that a
mixture of oligosaccharides, consisting of short-chain
galactooligosaccharides (scGOS) and long-chain fructooli-
gosaccharides (lcFOS), influenced immune response to an
influenza vaccine in mice by increasing vaccine-specific
delayed-type hypersensitivity (DTH) response and modu-
lating the lymphocyte T helper Th1/Th2 balance through
enhancement of Th1-related and suppression of Th2-
related parameters [54–57]. Regarding influenza vaccin-
ation, the hypothesis that the main immune cell type
involved is T cells is supported by the results obtained in
Bunout et al.’s clinical study, showing no influence of fruc-
tooligosaccharide consumption by healthy elderly on
immunoglobulin levels (IgA, IgM, IgG and salivary
secretory IgA) after influenza vaccine [58], which is
consistent with Udani’s results on arabinogalactan [32]. To
date, a beneficial immunological effect of larch arabinoga-
lactan was shown following challenges with Streptococcus
pneumoniae and tetanus vaccination only, through
increased concentration of antigen-specific IgG and IgE
antibodies in serum. In future investigations, the study of
different antibody isotypes could provide additional infor-
mation on the type of immune response elicited (IgG1 and
IgG3 indicating Th1-driven responses and IgG4 and IgE
indicating Th2-driven responses) [5]. While measuring
serum immune markers reflects in vivo response [5],
measuring antibody production would allow to investigate
the effect of larch arabinogalactan at the functional level.
Regarding influenza, it is not obvious to identify a role for
arabinogalactan in the improvement of the vaccine effect
using serum immunoglobulins as biomarkers. How-
ever, the study of markers such as lymphocyte activa-
tion (i.e. surface expression of activation markers on
CD8+ lymphocytes) or lymphocyte-derived mediators
(i.e. production of cytokines) could be more appropri-
ate according to the mode of action involved.
Conclusion
Common cold infections are both a health problem and
economic problem in Western countries, hence, it is
important to develop supportive solutions. Recent human
studies have demonstrated that dietary intervention with
arabinogalactan from North American Larix species could
increase resistance to infections. Larch arabinogalactan
seems to positively influence NK cells, macrophage activ-
ities and pro-inflammatory cytokine production. A clinical
study demonstrated that larch arabinogalactan supplemen-
tation reduced the incidence of common cold infections.
In two vaccine models (Streptococcus pneumoniae and
tetanus), larch arabinogalactan had an immunostimulatory
effect. Therefore, these results suggest a role for larch
arabinogalactan in the improvement of immune system
and defence against pathogens in humans. It is interesting
to note that both models (infection and vaccine) are
considered relevant by the European Food Safety Authority
(EFSA) to substantiate health claims on immune system in
the frame of European regulation (EC) 1924/2006 on
nutrition and health claims [59, 60].
To explain the mode of action, it has been suggested that
it can interact with the immune system either indirectly
through the production of SCFAs that affect inflammatory
responses via leukocytes function and cytokine production,
or directly through the capacity of M-cells to transfer intact
arabinogalactan through the intestinal barrier, delivering it
to immune cells (APC). However, the exact mode of action
is not yet completely understood and further studies are
required to better understand it and define more
precisely the benefits of larch arabinogalactan to the
immune system.
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